25-28 North Wall Quay
353 1 649 2000
|Dr. Colin Broom M.D.||Director||39,78k||N/A||1956|
|Mr. Daniel Dolan||Chief Financial Officer||445,69k||N/A||1977|
|Mr. J. Christopher Naftzger BA, Esq., J.D.||Interim CEO, Gen. Counsel & Sec.||N/A||N/A||1967|
|Ms. Jodi VanDerveer||Sr. VP & Head of HR||N/A||N/A||N/A|
|Dr. Christine J. Guico-Pabia M.B.A., M.D., M.P.H.||Chief Medical Officer||N/A||N/A||1963|
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Nabriva Therapeutics plcs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.